AR020998A1 - Formulaciones de liberacion controlada de metamizol - Google Patents

Formulaciones de liberacion controlada de metamizol

Info

Publication number
AR020998A1
AR020998A1 ARP990105435A ARP990105435A AR020998A1 AR 020998 A1 AR020998 A1 AR 020998A1 AR P990105435 A ARP990105435 A AR P990105435A AR P990105435 A ARP990105435 A AR P990105435A AR 020998 A1 AR020998 A1 AR 020998A1
Authority
AR
Argentina
Prior art keywords
controlled release
release formulations
metamizol
subjecting
active ingredient
Prior art date
Application number
ARP990105435A
Other languages
English (en)
Original Assignee
Formenti Farmaceutici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formenti Farmaceutici Spa filed Critical Formenti Farmaceutici Spa
Publication of AR020998A1 publication Critical patent/AR020998A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

Se obtienen formulaciones de liberacion controlada solidas, de administracion por vía oral al someter el ingrediente activo y un compuesto graso a procesode granulacion por fusion y mezclado posterior del granulado obtenido con un polímero hidrofílico y excipientes convencionales.
ARP990105435A 1998-11-03 1999-10-28 Formulaciones de liberacion controlada de metamizol AR020998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002365A IT1303693B1 (it) 1998-11-03 1998-11-03 Composizioni a rilascio controllato di metamizolo.

Publications (1)

Publication Number Publication Date
AR020998A1 true AR020998A1 (es) 2002-06-05

Family

ID=11380995

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105435A AR020998A1 (es) 1998-11-03 1999-10-28 Formulaciones de liberacion controlada de metamizol

Country Status (6)

Country Link
AR (1) AR020998A1 (es)
AU (1) AU1155000A (es)
CO (1) CO5160319A1 (es)
IT (1) IT1303693B1 (es)
PE (1) PE20001231A1 (es)
WO (1) WO2000025750A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19920415A1 (de) * 1999-05-04 2000-11-09 Hexal Ag Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
CA3013751C (en) * 2015-03-03 2023-08-08 Kindred Biosciences, Inc. Compositions and methods for treatment and prevention of pyrexia in horses
WO2018087109A1 (de) 2016-11-08 2018-05-17 Grünenthal GmbH Multipartikuläre arzneiform mit kontrollierter freisetzung von metamizol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712694D1 (de) * 1997-04-18 2006-08-24 Fritz Stanislaus Stabilisiertes arzneimittel enthaltend cysteinylderivate

Also Published As

Publication number Publication date
WO2000025750A1 (en) 2000-05-11
IT1303693B1 (it) 2001-02-23
CO5160319A1 (es) 2002-05-30
PE20001231A1 (es) 2000-11-29
AU1155000A (en) 2000-05-22
ITMI982365A1 (it) 2000-05-03

Similar Documents

Publication Publication Date Title
DE60120710D1 (de) Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
CA2377299A1 (en) Mesalazine controlled release oral pharmaceutical compositions
BR0209325A (pt) Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
MX9308188A (es) Glucomanano de konjac facilmente disponible, como un excipiente de liberacion sostenida.
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
NO20020939D0 (no) Oral administreringsform
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
CA2339913A1 (en) Pharmaceutical formulations and method for making
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
CO5170438A1 (es) Proceso para la preparacion de un comprimido de betahistina de liberacion controlada por granulacion en estado fundido y comprimido de liberacion controlada de betahistina obtenido mediante dicho proceso
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
AR020998A1 (es) Formulaciones de liberacion controlada de metamizol
ECSP993186A (es) Formulaciones de liberacion controlada de metamizol
ECSP003685A (es) Formulaciones orales de liberacion controlada
DE60103276D1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
ATE234608T1 (de) Mikrokapseln mit verzögerter freisetzung von wirkstoffen
ECSP003358A (es) Composiciones de betahistina de liberacion controlada
ECSP045185A (es) Formulación oral de fludara purísimo con liberación rápida del ingrediente activo
WO2020086705A3 (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations
PE20050017A1 (es) FORMULACION FARMACEUTICA QUE COMPRENDE 5-[2-ETOXI-5(4-METILPIPERAZIN-1-IL-SULFONIL) FENIL]-1,6-DIHIDRO-1-METIL-3-PROPILPIRAZOLO [4,3-d] PIRIMIDIN-7-ONA CITRATO Y PROCESO PARA SU FABRICACION